These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 31888931)

  • 1. AMEND study protocol: a case-control study to assess the long-term impact of invasive meningococcal disease in Australian adolescents and young adults.
    Marshall H; McMillan M; Wang B; Booy R; Afzali H; Buttery J; Blyth CC; Richmond P; Shaw D; Gordon D; Barton B
    BMJ Open; 2019 Dec; 9(12):e032583. PubMed ID: 31888931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 'Be on the TEAM' Study (Teenagers Against Meningitis): protocol for a controlled clinical trial evaluating the impact of 4CMenB or MenB-fHbp vaccination on the pharyngeal carriage of meningococci in adolescents.
    Carr J; Plested E; Aley P; Camara S; Davis K; MacLennan JM; Gray S; Faust SN; Borrow R; Christensen H; Trotter C; Maiden MCJ; Finn A; Snape MD;
    BMJ Open; 2020 Oct; 10(10):e037358. PubMed ID: 33093030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and impact of the 4CMenB vaccine against invasive serogroup B meningococcal disease and gonorrhoea in an infant, child, and adolescent programme: an observational cohort and case-control study.
    Wang B; Giles L; Andraweera P; McMillan M; Almond S; Beazley R; Mitchell J; Lally N; Ahoure M; Denehy E; Koehler A; Flood L; Marshall H
    Lancet Infect Dis; 2022 Jul; 22(7):1011-1020. PubMed ID: 35427492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term impact of invasive meningococcal disease in children: SEINE study protocol.
    Baloche A; Jung C; Levy M; Elbez-Rubinstein A; Béchet S; Layouni I; Monguillot G; Taha MK; Cohen R; Levy C
    PLoS One; 2022; 17(5):e0268536. PubMed ID: 35617288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Public Health Impact and Cost-Effectiveness Analysis of Routine Infant 4CMenB Vaccination in Germany to Prevent Serogroup B Invasive Meningococcal Disease.
    Scholz S; Schwarz M; Beck E; Meszaros K; Schneider M; Ultsch B; Greiner W
    Infect Dis Ther; 2022 Feb; 11(1):367-387. PubMed ID: 34877641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study.
    Viner RM; Booy R; Johnson H; Edmunds WJ; Hudson L; Bedford H; Kaczmarski E; Rajput K; Ramsay M; Christie D
    Lancet Neurol; 2012 Sep; 11(9):774-83. PubMed ID: 22863608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disease Burden of Invasive Meningococcal Disease in the Netherlands Between June 1999 and June 2011: A Subjective Role for Serogroup and Clonal Complex.
    Stoof SP; Rodenburg GD; Knol MJ; Rümke LW; Bovenkerk S; Berbers GA; Spanjaard L; van der Ende A; Sanders EA
    Clin Infect Dis; 2015 Oct; 61(8):1281-92. PubMed ID: 26123933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination vaccine against invasive meningococcal B and pneumococcal infections: potential epidemiological and economic impact in the Netherlands.
    Bos JM; Rümke HC; Welte R; Spanjaard L; van Alphen L; Postma MJ
    Pharmacoeconomics; 2006; 24(2):141-53. PubMed ID: 16460135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and economic burden of invasive meningococcal disease: Evidence from a large German claims database.
    Huang L; Heuer OD; Janßen S; Häckl D; Schmedt N
    PLoS One; 2020; 15(1):e0228020. PubMed ID: 31990941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The inpatient costs and hospital service use associated with invasive meningococcal disease in South Australian children.
    Wang B; Haji Ali Afzali H; Marshall H
    Vaccine; 2014 Aug; 32(37):4791-8. PubMed ID: 24998605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B Part of It School Leaver protocol: an observational repeat cross-sectional study to assess the impact of a meningococcal serogroup B (4CMenB) vaccine programme on carriage of
    Marshall HS; McMillan M; Koehler A; Lawrence A; MacLennan J; Maiden M; Ramsay M; Ladhani SN; Trotter C; Borrow R; Finn A; Sullivan T; Richmond P; Kahler C; Whelan J; Vadivelu K
    BMJ Open; 2019 May; 9(5):e027233. PubMed ID: 31064808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lifetime costs of invasive meningococcal disease: A Markov model approach.
    Wang B; Haji Ali Afzali H; Giles L; Marshall H
    Vaccine; 2019 Oct; 37(46):6885-6893. PubMed ID: 31594708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Health Burden of Invasive Meningococcal Disease: A Systematic Review.
    Strifler L; Morris SK; Dang V; Tu HA; Minhas RS; Jamieson FB; Deeks SL; Crowcroft NS; Sander B
    J Pediatric Infect Dis Soc; 2016 Dec; 5(4):417-430. PubMed ID: 26501470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling the public health impact of different meningococcal vaccination strategies with 4CMenB and MenACWY versus the current toddler MenACWY National Immunization Program in Chile.
    Graña MG; Cavada G; Vasquez M; Shen J; Maervoet J; Klint J; Gómez JA
    Hum Vaccin Immunother; 2021 Dec; 17(12):5603-5613. PubMed ID: 34890520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First statewide meningococcal B vaccine program in infants, children and adolescents: evidence for implementation in South Australia.
    Marshall HS; Lally N; Flood L; Phillips P
    Med J Aust; 2020 Feb; 212(2):89-93. PubMed ID: 31909501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changing patterns of invasive meningococcal disease and future immunization strategies.
    Taha MK; Bekkat-Berkani R; Abitbol V
    Hum Vaccin Immunother; 2023 Dec; 19(1):2186111. PubMed ID: 37017273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cost-of-illness for invasive meningococcal disease caused by serogroup B Neisseria meningitidis (MenB) in Germany.
    Scholz S; Koerber F; Meszaros K; Fassbender RM; Ultsch B; Welte RR; Greiner W
    Vaccine; 2019 Mar; 37(12):1692-1701. PubMed ID: 30661834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of meningococcal polysaccharide serogroups A, C, W-135 and Y conjugate vaccine in Australian adolescents.
    Si S; Zomer E; Fletcher S; Lee J; Liew D
    Vaccine; 2019 Aug; 37(35):5009-5015. PubMed ID: 31301916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Australian Meningococcal Surveillance Programme annual report, 2015.
    Lahra MM; Enriquez RP;
    Commun Dis Intell Q Rep; 2016 Dec; 40(4):E503-E511. PubMed ID: 28043225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B Part of It protocol: a cluster randomised controlled trial to assess the impact of 4CMenB vaccine on pharyngeal carriage of
    Marshall HS; McMillan M; Koehler A; Lawrence A; MacLennan JM; Maiden MCJ; Ramsay M; Ladhani SN; Trotter C; Borrow R; Finn A; Sullivan T; Richmond P; Kahler CM; Whelan J; Vadivelu K
    BMJ Open; 2018 Jul; 8(7):e020988. PubMed ID: 29991629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.